Followers | 14 |
Posts | 909 |
Boards Moderated | 0 |
Alias Born | 09/29/2016 |
Monday, February 13, 2017 9:39:53 AM
DCF Analysis
Recent INCY News
- Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease • PR Newswire (US) • 09/18/2024 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:24:17 PM
- Retifanlimab (Zynyz®) von Incyte verlängert progressionsfreies Überleben bei Patienten mit Plattenepithel-Analkarzinom (SCAC) – Datenpräsentation beim ESMO Presidential Symposium 2024 • Business Wire • 09/15/2024 10:36:00 PM
- Incyte’s CDK2 Inhibitor INCB123667 zeigt vielversprechende Anzeichen von klinischer Wirkung bei Patienten mit soliden Tumoren in fortgeschrittenem Stadium • Business Wire • 09/15/2024 05:34:00 AM
- INCB123667, l'inhibiteur de la CDK2 d'Incyte, montre des signes prometteurs d'activité clinique chez des patientes atteintes de tumeurs solides avancées, notamment le cancer de l'ovaire • Business Wire • 09/15/2024 05:34:00 AM
- Le rétifanlimab (Zynyz®) d’Incyte prolonge la survie sans progression chez les patients atteints de carcinome épidermoïde du canal anal (SCAC) ; des données ont été présentées lors du Symposium présidentiel de l’ESMO 2024 • Business Wire • 09/15/2024 04:48:00 AM
- Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer • Business Wire • 09/14/2024 04:45:00 PM
- Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium • Business Wire • 09/14/2024 02:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 08:06:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:17:21 PM
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/09/2024 08:30:00 PM
- Incyte présentera les résultats de la phase 3 de Retifanlimab (Zynyz®) et les données initiales du programme d'inhibiteurs de CDK2 de phase 1 à l'édition 2024 du Congrès de la Société européenne d'oncologie médicale (ESMO) • Business Wire • 08/21/2024 08:49:00 PM
- Incyte präsentiert bahnbrechende Phase 3-Ergebnisse für Retifanlimab (Zynyz®) und erste Daten aus Phase 1 des CDK2-Inhibitor-Programms auf dem Kongress der European Society of Medical Oncology (ESMO) 2024 • Business Wire • 08/21/2024 08:49:00 PM
- Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 • Business Wire • 08/21/2024 03:40:00 PM
- Incyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekannt • Business Wire • 08/16/2024 09:59:00 AM
- Incyte annonce des résultats positifs de l'étude pivot sur le tafasitamab (Monjuvi®) dans le lymphome folliculaire récidivant ou réfractaire • Business Wire • 08/16/2024 09:46:00 AM
- Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma • Business Wire • 08/15/2024 08:30:00 PM
- Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD) • Business Wire • 08/15/2024 08:15:00 PM
- Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD) • Business Wire • 08/15/2024 10:26:00 AM
- Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) • Business Wire • 08/14/2024 09:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 07:37:17 PM
- Incyte to Present at Upcoming Investor Conferences • Business Wire • 08/13/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:39:53 PM
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/07/2024 09:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM